Institutional members access full text with Ovid®

Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients

Canestri, Anaa,c; Krivine, Anneb; Assoumou, Lambertc; Le Corre, Moniqued; Rozenberg, Floreb; Marcelin, Anne-Genevièvec,e,f; Schneider, Luminitaa,c; Samri, Assiad; Carcelain, Guislainea,e,g; Autran, Brigittea,e,g; Katlama, Christinea,c,e; Guihot, Améliea,e,g

doi: 10.1097/QAD.0b013e3283402bc1
Research Letters

Immune changes induced by the CCR5 antagonist maraviroc raise the question of an impairment of responses to vaccines. We evaluated the immunogenicity of the adjuvanted pandemic influenza A-H1N1v 2009 vaccine in HIV-1-infected patients with suppressed HIV viremia with or without a maraviroc-containing regimen. Seroprotection, seroconversion, and geometric mean titer ratio of specific antibody titers did not differ between groups. These results suggest that maraviroc does not significantly affect the immune response to this adjuvanted vaccine.

aAP-HP, Hôpital Pitié-Salpêtrière, Maladies Infectieuses et Tropicales, France

bAP-HP, Hôpital Saint Vincent Paul, Laboratoire de Virologie, France

cINSERM, UMR 943, France

dINSERM, UMR S945, France

eUniversité Pierre et Marie Curie- Paris 6, France

fAP-HP, Hôpital Pitié Salpêtrière, Laboratoire de Virologie, France

gAP-HP, Hôpital Pitié Salpêtrière, Laboratoire d'Immunologie cellulaire et tissulaire, Paris, France.

Received 2 August, 2010

Revised 1 September, 2010

Accepted 2 September, 2010

Correspondence to Dr Ana Canestri, Service des Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris, France. Tel: +33 1 42 16 01 03; fax: +33 1 42 16 01 65; e-mail:

© 2010 Lippincott Williams & Wilkins, Inc.